Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers, commonly referred to as luminal-like breast cancers, account for 70–80% of all breast cancer cases and are a major contributor to breast cancer-related deaths, presenting a global health challenge [1–3]. Here, ERBB2 is linked to breast carcinoma.